MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Feb. 16, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its fourth quarter and fiscal year-end 2022 financial results on Thursday, February 23, 2023, at 8:30 AM Eastern time.
Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call to discuss the results as follows:
| Time | 8:30 A.M EST |
| Toll free (U.S.) | 1-833-630-1956 |
| International (U.S) | 1-412-317-1837 |
| Germany | 0800-6647650 |
| Israel | 1-80-9212373 |
| Access Code | Please ask to join into the ReWalk Robotics Ltd. call |
| Webcast (live and replay) | https://edge.media-server.com/mmc/p/z32t5emd under the ‘Investors’ section'. |
The archived webcast will be available via the following link https://edge.media-server.com/mmc/p/z32t5emd or through the 'Investors' section' on www.rewalk.com.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke. ReWalk’s mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit www.rewalk.com.
ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel and the Unites States.
Investor Contact:
Michael Lawless
Chief Financial Officer
ReWalk Robotics Ltd.
T: +1 508-281-7274
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.67 |
| Daily Change: | -0.0027 -0.40 |
| Daily Volume: | 1,029,050 |
| Market Cap: | US$7.120M |
May 19, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
